2008
DOI: 10.1007/s00417-008-0774-y
|View full text |Cite
|
Sign up to set email alerts
|

Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR)

Abstract: IVB administered prior to vitrectomy was well tolerated and reduced active neovascularization, thus facilitating PPV.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

7
145
2
11

Year Published

2008
2008
2023
2023

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 173 publications
(165 citation statements)
references
References 35 publications
7
145
2
11
Order By: Relevance
“…32,33 More recently, intravitreal anti-VEGF therapy with bevacizumab administered 1-2 weeks pre-operatively has been reported to provide some benefit. [34][35][36] Early vitreous cavity haemorrhages usually clear spontaneously within 2-6 weeks without requiring further intervention.…”
Section: Complications After Diabetic Vitrectomymentioning
confidence: 99%
See 1 more Smart Citation
“…32,33 More recently, intravitreal anti-VEGF therapy with bevacizumab administered 1-2 weeks pre-operatively has been reported to provide some benefit. [34][35][36] Early vitreous cavity haemorrhages usually clear spontaneously within 2-6 weeks without requiring further intervention.…”
Section: Complications After Diabetic Vitrectomymentioning
confidence: 99%
“…Intravitreal bevacizumab administered 1-2 weeks pre-operatively has been reported to facilitate surgical dissection of fibrovascular membranes in eyes with severe active PDR. 35,36,[65][66][67] The risk of recurrent vitreous cavity haemorrhage may also be reduced by this treatment. 34 However, there is a potential adverse effect because fibrovascular membrane contraction can lead to rapid development or progression of tractional retinal detachment.…”
Section: Adjunctive Pharmacotherapymentioning
confidence: 99%
“…This vascular endothelial growth factor inhibitor has been reported to decrease intraoperative hemorrhage and facilitate fibrovascular membrane dissection, [3][4][5][6][7][8][9][10][11][12] and reduce postoperative vitreous hemorrhage (VH) rates. 9,[12][13][14] However, these studies were limited by relatively small numbers, heterogeneous retinal pathology (TRD and VH were studied together), and varying surgical techniques (multiple surgeons and multiple gauge vitrectomies).…”
Section: Introductionmentioning
confidence: 99%
“…Bevacizumab has been used preoperatively as an adjuvant in vitrectomy in patients with TRD, vitreal hemorrhage, mixed TRD, active fibrovascular proliferation (FVP) (3,(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30) , and neovascular glaucoma (31) (Table 1). Also, a pilot study of bevacizumab injected immediately after vitrectomy for vitreous hemorrhage was conducted (32) .…”
Section: Preoperative Administration Of Anti-vegf Drugs Before Pars Pmentioning
confidence: 99%